Clinical Rheumatology

, Volume 34, Issue 11, pp 1839–1846 | Cite as

Enthesitis-related arthritis

  • Amita Aggarwal
  • Durga Prasanna Misra
Review Article


Juvenile idiopathic arthritis (JIA) is the most common chronic arthritis of childhood. Currently, it is characterized by seven categories. The enthesitis-related arthritis (ERA) category usually affects boys older than 6 years and presents with lower limb asymmetrical arthritis associated with enthesitis. Later, these children can develop inflammatory lumbosacral pain (IBP). These children are at risk of developing acute anterior uveitis. A recently devised disease activity index, Juvenile Spondyloarthropathy Disease Activity Index (JSpADA), has been validated in retrospective cohorts. The corner stone of treatment is NSAIDs, local corticosteroid injections, and exercise. Methotrexate and sulfasalazine can be used for peripheral arthritis while anti-tumor necrosis factor (TNF) agents are sometimes used to treat refractory enthesitis and sacroiliitis. Almost two third of patients with ERA have persistent disease and often have impairments in their quality of life. The presence of hip or ankle arthritis and a family history of spondyloarthropathy or polyarticular joint involvement at onset are associated with poorer prognosis.


Enthesitis-related arthritis Juvenile idiopathic arthritis Outcomes Pathogenesis Prognosis Treatment 





  1. 1.
    Petty RE, Southwood TR, Manners P et al (2001) International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision. Edmonton J Rheumatol 31:390–392Google Scholar
  2. 2.
    Rosenberg AM, Petty RE (1982) A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 125:1041–1047CrossRefGoogle Scholar
  3. 3.
    Oen K, Tucker L, Huber AM et al (2009) Predictors of early inactive disease in a juvenile idiopathic arthritis cohort: results of a Canadian multicenter, prospective inception cohort study. Arthritis Rheum 61:1077–1086CrossRefPubMedGoogle Scholar
  4. 4.
    Kunjir V, Venuopalan A, Chopra A (2010) Disease using the ILAR classification criteria for JIA: a community-based profile of Indian patients with juvenile onset chronic inflammatory joint disease using the ILAR classification criteria for JIA: a community-based cohort study. J Rheumatol 37:1756–1762CrossRefPubMedGoogle Scholar
  5. 5.
    Saurenmann RK, Rose JB, Tyrrell P et al (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56:1974–1984CrossRefPubMedGoogle Scholar
  6. 6.
    Hinks A, Martin P, Flynn E et al (2011) Subtype specific genetic associations for juvenile idiopathic arthritis: ERAP1 with the enthesitis related arthritis subtype and IL23R with juvenile psoriatic arthritis. Arthritis Res Ther 13(1):R12PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Saxena N, Misra R, Aggarwal A (2006) Is the enthesitis-related arthritis subtype of juvenile idiopathic arthritis a form of chronic reactive arthritis? Rheumatology 45:1129–1132CrossRefPubMedGoogle Scholar
  8. 8.
    Ramanathan A, Srinivasulu H, Colbert RA (2013) Update on juvenile spondyloarthropathy. Rheum Dis Clin N Am 39:767–788CrossRefGoogle Scholar
  9. 9.
    Aggarwal A, Agarwal S, Misra R (2007) Chemokine and chemokine receptor analysis reveals elevated interferon-inducible protein-10 (IP)-10/CXCL10 levels and increased number of CCR5+ and CXCR3+ CD4 T cells in synovial fluid of patients with enthesitis-related arthritis (ERA). Clin Exp Immunol 148:515–519PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Saxena N, Aggarwal A, Misra R (2007) Elevated concentrations of monocyte derived cytokines in synovial fluid of children with enthesitis related arthritis and polyarticular types of juvenile idiopathic arthritis. J Rheumatol 32:1349–1353Google Scholar
  11. 11.
    Myles A, Aggarwal A (2011) Expression of Toll-like receptors 2 and 4 is increased in peripheral blood and synovial fluid monocytes of patients with enthesitis-related arthritis subtype of juvenile idiopathic arthritis. Rheumatology (Oxford) 50:481–488CrossRefGoogle Scholar
  12. 12.
    Zeng L, Lindstrom MJ, Smith JA (2011) Ankylosing spondylitis macrophage production of higher levels of interleukin-23 in response to lipopolysaccharide without induction of a significant unfolded protein response. Arthritis Rheum 63:3807–3817PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Mahendra A, Misra R, Aggarwal A (2009) Th1 and Th17 predominance in the enthesitis-related arthritis form of juvenile idiopathic arthritis. J Rheumatol 36:1730–1736CrossRefPubMedGoogle Scholar
  14. 14.
    Chan AT, Kollnberger SD, Wedderburn LR et al (2005) Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis. Arthritis Rheum 52:3586–3595CrossRefPubMedGoogle Scholar
  15. 15.
    D’Agostino MA, Said-Nahal R, Hacquard-Bouder C et al (2003) Assessment of peripheral enthesitis in the spon-dylarthropathies by ultrasonography combined with power Doppler: a cross-sectional study. Arthritis Rheum 48:523–533CrossRefPubMedGoogle Scholar
  16. 16.
    Weiss PF, Klink AJ, Behrens EM et al (2011) Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res 63:1307–1312CrossRefGoogle Scholar
  17. 17.
    Giannini EH, Ruperto N, Ravelli A et al (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 40:1202–1209CrossRefPubMedGoogle Scholar
  18. 18.
    Aquino MR, Tse SM, Gupta S et al (2015) Whole-body MRI of juvenile spondyloarthritis: protocols and pictorial review of characteristic patterns. Pediatr Radiol 45:754–762CrossRefPubMedGoogle Scholar
  19. 19.
    Gensler LS, Ward MM, Reviella JD et al (2008) Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 67:233–237CrossRefPubMedGoogle Scholar
  20. 20.
    Stoll ML, Bhore R, Dempsey-Robertson M et al (2010) Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 37:2402–2408PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Oen K, Duffy CM, Tse SM et al (2010) Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res 62:527–536CrossRefGoogle Scholar
  22. 22.
    Pagnini I, Sevelli S, Matucci-Cerinic M et al (2010) Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 37:2395–2401CrossRefPubMedGoogle Scholar
  23. 23.
    Petty RE, Cassidy JT (2011) Enthesitis-related arthritis (juvenile ankylosing spondylitis). In: Cassidy JT (ed) Textbook of pediatric rheumatology, 6th edn. Saunders Elsevier Publishers, Philadelphia, pp 272–280CrossRefGoogle Scholar
  24. 24.
    Stoll ML, Patel AS, Punaro M et al (2012) MR enterography to evaluate sub-clinical intestinal inflammation in children with spondyloarthritis. Pediatr Rheumatol Online J 10:6PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Reimold AM, Chandran V (2014) Nonpharmacologic therapies in spondyloarthritis. Best Pract Res Clin Rheumatol 28:779–792CrossRefPubMedGoogle Scholar
  26. 26.
    Ozgocmen S, Akgul O, Altay Z et al (2012) Expert opinion and key recommendations for the physical therapy and rehabilitation of patients with ankylosing spondylitis. Int J Rheum Dis 15:229–238CrossRefPubMedGoogle Scholar
  27. 27.
    Haroon N, Kim T, Inman RD (2012) NSAIDs and radiographic progression in ankylosing spondylitis. Bagging big game with small arms? Ann Rheum Dis 71:1593–1595CrossRefPubMedGoogle Scholar
  28. 28.
    Beukelman T, Patkar NM, Saag KG et al (2011) 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 63:465–482CrossRefGoogle Scholar
  29. 29.
    Poddubnyy D (2013) Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Disord 5:45–54CrossRefGoogle Scholar
  30. 30.
    Poddubnyy D, van der Heijde D (2012) Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. Rheum Dis Clin N Am 38:601–611CrossRefGoogle Scholar
  31. 31.
    Marti P, Molinari L, Bolt IB et al (2008) Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis. Eur J Pediatr 167:425–430CrossRefPubMedGoogle Scholar
  32. 32.
    Van Rossum MAJ, van Soesbergen RM, Boers M et al (2007) Long-term outcome of juvenile idiopathic arthritis following a placebo-controlled trial: sustained benefits of early sulfasalazine treatment. Ann Rheum Dis 66:1518–1524PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    van Rossum MA, Fiselier TJ, Franssen MJ et al (1998) Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 41:808–816CrossRefPubMedGoogle Scholar
  34. 34.
    Tse SM, Burgos-Vargas R, Laxer RM (2005) Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 52:2103–2108CrossRefPubMedGoogle Scholar
  35. 35.
    Otten MH, Prince FH, Twilt M et al (2011) Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis—data from the Dutch arthritis and biological in children register, 1999–2010. J Rheumatol 38:2258–2263CrossRefPubMedGoogle Scholar
  36. 36.
    Horneff G, Burgos-Vargas R, Constantin T et al (2014) Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study. Ann Rheum Dis 73:1114–1122PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    Horneff G, Foeldvari I, Minden K et al (2015) Efficacy and safety of etanercept in enthesitis-related arthritis juvenile idiopathic arthritis: results from a phase 3 randomized double-blind study. Arthritis Rheumatol. doi: 10.1002/art.39145 PubMedGoogle Scholar
  38. 38.
    Horneff G, Fitter S, Foeldvari I et al (2012) Double-blind, placebo-controlled randomized trial with adalimumab for treatment of juvenile onset ankylosing spondylitis (JoAS): significant short term improvement. Arthritis Res Ther 14:R230PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Haroon N, Inman RD, Learch TJ et al (2013) The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65:2645–2654PubMedCentralPubMedGoogle Scholar
  40. 40.
    Wallace CA, Ruperto N, Giannini E et al (2004) Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheum 31:2290–2294PubMedGoogle Scholar
  41. 41.
    Prince FHM, Twilt M, Simon SCM et al (2009) When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 68:1228–1229CrossRefPubMedGoogle Scholar
  42. 42.
    Prince FHM, Twilt M, ten Cate R et al (2009) Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 68:635–641CrossRefPubMedGoogle Scholar
  43. 43.
    Gerloni V, Pontikaki I, Gattinara M et al (2008) Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann Rheum Dis 67:1145–1152CrossRefPubMedGoogle Scholar
  44. 44.
    Weiss PF, Colbert RA, Xiao R et al (2014) Development and retrospective validation of the juvenile spondyloarthritis disease activity index. Arthritis Care Res 66:1775–1782CrossRefGoogle Scholar
  45. 45.
    Berntson L, Damgård M, Andersson-Gäre B et al (2008) HLA-B27 predicts a more extended disease with increasing age at onset in boys with juvenile idiopathic arthritis. J Rheumatol 35:2055–2061PubMedGoogle Scholar
  46. 46.
    Colbert RA (2010) Classification of juvenile spondyloarthritis: enthesitis-related arthritis and beyond. Nat Rev Rheumatol 6:477–485PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Selvaag AM, Lien G, Sørskaar D et al (2005) Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J Rheumatol 32:1122–1130PubMedGoogle Scholar
  48. 48.
    Flatø B, Hoffmann-Vold AM, Reiff A et al (2006) Long-term outcome and prognostic factors in enthesitis-related arthritis: a case–control study. Arthritis Rheum 54:3573–3582CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2015

Authors and Affiliations

  1. 1.Department of Clinical ImmunologySanjay Gandhi Postgraduate Institute of Medical SciencesLucknowIndia

Personalised recommendations